Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124981892 | 12498189 | 2 | F | 20160627 | 20160627 | 20160705 | EXP | JP-009507513-1606JPN012024 | MERCK | 0.00 | M | Y | 0.00000 | 20160705 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124981892 | 12498189 | 1 | PS | PEGINTERFERON ALFA-2B | PEGINTERFERON ALFA-2B | 1 | Subcutaneous | DAILY DOSAGE UNKNOWN | U | 103949 | POWDER FOR INJECTION | ||||||||
| 124981892 | 12498189 | 2 | SS | RIBAVIRIN. | RIBAVIRIN | 1 | Oral | DAILY DOSAGE UNKNOWN | U | 0 | CAPSULE | ||||||||
| 124981892 | 12498189 | 3 | SS | TELAPREVIR | TELAPREVIR | 1 | Unknown | DAILY DOSAGE UNKNOWN | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124981892 | 12498189 | 1 | Hepatitis C |
| 124981892 | 12498189 | 2 | Hepatitis C |
| 124981892 | 12498189 | 3 | Hepatitis C |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124981892 | 12498189 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124981892 | 12498189 | Hepatitis C | |
| 124981892 | 12498189 | Viral mutation identified |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |